Sorrento Therapeutics Inc (SRNE)

[James salmon]

Maybe you forgot about this;

Specifically, as previously disclosed, in April 2019, the Company filed an arbitration demand against NantPharma, LLC (“NantPharma”) and its Chief Executive Officer Patrick Soon-Shiong, seeking several hundred million dollars in damages for alleged breaches of the Stock Sale and Purchase Agreement, dated May 14, 2015, entered into between NantPharma and the Company, arising out of NantPharma’s purchase of the drug Cynviloq™ from the Company in May 2015. Sorrento’s claims against NantPharma remain pending before the American Arbitration Association, and have been submitted to the arbitrator for a decision, which is currently expected later this year.


There is probably a lot pending on this outcome which is due any-day now.